Edesa Biotech, Inc. SBOT Income Statement

Edesa biotech, inc. (SBOT)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Aug'14	Jun'14	Mar'14	Dec'13
Revenues:
Revenue from Contract with Customer
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product sales
-	-	-	-	-	-	-	-	-	-	-	-	612	925	1,239	1,119	1,050	867	563	480	380	280	143	0	0	0
Contract services revenue
-	-	-	-	-	-	-	-	-	-	-	-	0	-	32	77	122	167	195	195	210	237	192	0	0	0
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36	0	0	0
Product sales and services
629	518	410	127	127	191	211	87	107	106	228	501	662	925	1,271	1,196	1,172	1,034	758	684	599	525	372	0	0	0
Product sales and services
629	518	410	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Expenses:
Cost of sales
0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs of contract services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Cost of sales
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0
Cost of sales
-	-	-	-	-	-	133	0	0	0	-	0	0	-	818	710	822	796	580	0	0	0	-	-	-	-
Costs of aquaculture
-	-	-	-	-	-	312	313	308	297	284	298	293	309	309	281	275	263	259	0	0	0	-	-	-	-
Grant costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36	0	0	0
Research and development
2,015	1,624	1,353	1,536	1,331	1,713	2,087	2,070	2,308	2,143	1,973	1,987	1,921	1,901	1,729	1,267	926	899	1,029	1,464	1,878	2,329	2,458	0	0	0
General and administrative
3,411	2,727	2,193	2,576	1,882	2,227	2,757	2,207	2,719	2,691	2,944	3,041	3,126	3,145	3,322	3,476	3,374	3,395	3,227	2,937	2,931	2,792	2,871	0	0	0
Total expenses
5,542	4,456	3,648	1,650	751	1,618	2,623	4,612	5,504	5,306	5,452	5,673	5,729	5,940	6,180	5,735	5,399	5,354	5,097	5,385	5,696	5,874	6,090	0	0	0
Loss from operations
-4,913	-3,937	-3,237	-4,189	-3,291	-4,094	-5,078	-4,524	-5,396	-5,199	-5,224	-5,172	-5,067	-5,015	-4,908	0	0	0	-	-	-	-	-	-	-	-
Other income (loss):
Gain (loss) in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-211	-536	717	1,779	2,131	-911	2,362	1,486	-2,533	0	0	0
Interest income
73	71	73	91	91	83	75	39	32	33	32	32	26	25	24	22	37	47	54	65	62	59	61	0	0	0
Foreign exchange gain (loss)
8	-3	23	34	19	7	-35	99	170	221	162	-10	-82	108	76	-152	-67	-601	-653	-561	-492	-367	-222	0	0	0
Gain on disposition of property and equipment
-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income (loss)
82	67	96	118	102	82	31	139	202	255	194	22	-56	134	-110	-666	687	1,225	1,532	-1,407	1,933	1,178	-2,693	0	0	0
Loss before income taxes
0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss Before Income Tax
-	-	-	-	-	-	-5,038	-5,130	-5,193	-4,944	-5,029	-5,150	-5,123	-4,881	-5,018	-5,206	-3,539	-3,095	-2,806	-6,108	-3,164	-4,169	-8,412	0	0	0
Income tax expense
0	0	-	-	0	0	0	0	0	0	0	0	0	0	7	16	25	34	36	33	33	36	27	0	0	0
Net loss
-4,831	-3,871	-3,141	-1,595	-712	-1,536	-2,572	-4,386	-5,194	-4,945	-5,030	-5,150	-5,124	-4,881	-5,026	-5,222	-3,564	-3,129	-2,843	-6,142	-3,198	-4,205	-8,439	0	0	0
Exchange differences on translation
-7	106	105	137	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss and comprehensive loss
-4,839	-3,765	-3,035	-2,461	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss and Comprehensive Loss
-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-1.05	0.04	-0.02	-0.08
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05	-	-	-1.05	0.04	-0.02	-0.08
Weighted average number of common shares
8,740	7,504	7,551	4,317	3,239	3,239	4,976	3,239	1,502	1,502	-7,184	1,450	1,448	10,136	-20,227	8,448	8,448	8,373	-	-	7,954	7,946	-	-	-	-
Loss per share - basic and diluted
-0.17	-0.15	-0.09	-0.30	-0.16	-0.11	0.67	-0.13	-0.90	-0.93	-1.69	-0.84	-0.76	-0.15	-3.56	-0.14	-0.10	-0.19	-	-	-0.05	-0.17	-	-	-	-
Basic (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,954	-	-	-196,122	76,237	76,237	73,978
Diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,502	-	-	-206,784	86,898	76,237	73,978
Product [Member]
Revenue from Contract with Customer
-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-